Qualigen Therapeutics Secures Worldwide Rights to G4-Selective Transcription Inhibitors from University College London to Develop as Cancer Therapeutics
January 18, 2022
Todos Medical Announces New cPass Neutralizing Antibody Testing Reference Lab Agreement for CLIA/CAP Lab Provista with Physician Group in 40 States
December 22, 2021
Related Post
-
-
Neuropathix, Inc. Receives Patent Grant from India for Its Novel Anti-Inflammatory Compounds
January 18, 2022
-
Aditxt Provides Online Business Update Townhall Meeting with Amro Albanna, Co-Founder & CEO
January 12, 2022
-
Todos Medical to Announce Topline Results from Tollovir(TM) Phase 2 Clinical Trial from the Treatment of Hospitalized COVID-19 Patients on January 27th, 2022
January 12, 2022